What’s new

• Revenue hit ₹137.42 cr in FY26 with EBITDA margins at 37.5%.
• Management targets ₹330 cr revenue and ₹150 cr profit from female condoms by end-FY27.
• Capacity expansion plans aim for 806 million units total.

Why it matters

Anondita is betting heavily on the female condom market to reach a ₹1,000 cr revenue goal within two years. While the growth is rapid, the gap between current performance and these aggressive targets introduces significant execution risk.

What we’re watching

• The timeline for securing pending UN certification.
• Progress on the South African government contract.
• Whether actual margins hold up as the company scales production.

The full read

Anondita Medicare posted a 78.5% revenue increase to ₹137.42 crore for FY26, with EBITDA margins reaching 37.5%. Management is now looking toward a ₹1,000 crore revenue target within two years. The plan hinges on scaling female condom production to 240 million units by the end of FY27, aiming for ₹330 crore in revenue and ₹150 crore in profit from that segment alone. Total capacity is slated to reach 806 million units. International expansion is also in play, with a contract secured in South Africa and UN certification pending. While the growth trajectory is steep, the company faces clear execution risks in meeting these ambitious targets. Investors should monitor whether the company can bridge the distance between its current scale and these forward-looking projections.

Primary source: NSE